NMN and Mogroside Composition for Lower-Cost Metabolic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds and extracts for obesity, hyperlipidemia, and hyperglycemia, such as β-nicotinamide mononucleotide (NMN) and mogroside, are costly and lack synergistic effects in inhibiting adipocyte growth and promoting islet cell viability, making them less effective and economically unfeasible for widespread application.
Innovation Solution
A composition combining nicotinamide mononucleotide and mogroside, particularly mogroside V, is formulated with a molar ratio of 1-100:0.1-1000, using a specific extraction method involving Corsvenor Momordica Fruit extract, to achieve synergistic effects in inhibiting adipocyte growth and promoting islet cell viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NMN is used alone to promote islet cell viability and control blood glucose, then therapeutic effect is achieved, but manufacturing cost is extremely high
Solution Approach 1:
The patent combines NMN with mogroside V in a specific formulation to achieve synergistic effects. This combination allows for reduced NMN dosage while maintaining or enhancing therapeutic efficacy, thereby lowering the overall manufacturing cost. The synergistic interaction between the two compounds addresses both the reliability of therapeutic effect and the cost of manufacture.
Solution Approach 2:
The patent introduces mogroside V, a lower-cost compound, to partially replace expensive NMN in the formulation. Mogroside V provides complementary benefits including fat accumulation inhibition and potential islet cell protection, allowing the formulation to achieve therapeutic goals with less reliance on the expensive NMN component.
2Reliability
If NMN is used alone to control blood glucose, then blood glucose control is achieved, but cost of use is extremely high
Solution Approach 1:
By merging NMN with mogroside V in a synergistic formulation, the patent achieves effective blood glucose control with reduced NMN dosage. The combination leverages the hypoglycemic effects of both compounds, providing sustained glucose control at lower overall cost.
Solution Approach 2:
Mogroside V adds multiple functions to the formulation beyond just blood glucose control, including fat accumulation inhibition and potential islet cell protection. This multi-functionality allows the formulation to address multiple metabolic issues simultaneously, reducing the need for additional separate treatments and lowering overall cost of use.
3Reliability
If high dosage of NMN is used to achieve anti-aging effect, then anti-aging effect is confirmed, but cost reaches tens of thousands to millions per person per year
Solution Approach 1:
The patent combines NMN with mogroside V to create a synergistic formulation that may achieve anti-aging effects at lower NMN dosages. The combination leverages the complementary mechanisms of both compounds, potentially maintaining efficacy while reducing the expensive NMN component.
Solution Approach 2:
The patent changes the formulation parameters by introducing a second active ingredient (mogroside V) and optimizing the dosage ratio between NMN and mogroside V. This parameter change allows for reduced NMN dosage while maintaining or enhancing the anti-aging effect, thereby reducing cost.
4Reliability
If mogroside is used to inhibit adipocyte growth and reduce fat accumulation, then fat control effect is achieved, but effect strength is weak when used alone
Solution Approach 1:
The patent combines mogroside V with NMN to create a synergistic formulation where NMN enhances the fat control effects of mogroside V. The combination leverages the adipocyte-inhibiting properties of mogroside V while NMN provides additional metabolic support, resulting in stronger overall fat control effect than either compound alone.
Data Source
AI summary
The present invention belongs to the medical and technical field and provides a medicine or health food composition of nicotinamide mononucleotide and mogroside. In addition, the present invention also provides the preparation method, formulation and application of the composition.